AEMPS of Spain revokes previous approval for the Active Cancer Immunotherapy, OBI-822, to proceed to Phase III Clinical Trial

1.Date of occurrence of the event:2022/04/06 2.New drug name or code:Active Cancer Immunotherapy OBI-822 (Adagloxad Simolenin) 3.Indication:OBI-822 is a therapeutic cancer vaccine classified as active cancer immunotherapy. Globo H-KLH conjugate triggers immune response against hard-to-treat cancers once injected into the human system. Clinical trial info: https://www.clinicaltrials.gov/ct2/show/NCT03562637 https://www1.cde.org.tw/ct_taiwan/search_case2.php?caseno_ind%5B2%5D=2681 4.Planned development stages:Phase III clinical trial and New […]